Revance Therapeutics is a biotechnology company focused on developing and commercializing innovative products for aesthetic and therapeutic applications. The company's lead product, DaxibotulinumtoxinA for Injection, is a novel botulinum toxin that has the potential to be a best-in-class product for the treatment of glabellar lines and other aesthetic and therapeutic indications. Revance Therapeutics was founded in 2002 and is headquartered in Newark, California.
Learn more about Revance Therapeutics